Patient Unique Stigmatization Holistic tool in dermatology (PUSH-D): Development and validation of a dermatology-specific stigmatization assessment tool
- PMID: 36201355
- PMCID: PMC10092236
- DOI: 10.1111/jdv.18641
Patient Unique Stigmatization Holistic tool in dermatology (PUSH-D): Development and validation of a dermatology-specific stigmatization assessment tool
Abstract
Background: The skin plays an important role in establishing interpersonal relationships, and thus visible skin disorders, which have a significant impact on physical appearance, influence other people's behaviours and attitudes.
Objective: To develop and validate a dermatologic-specific questionnaire to evaluate stigmatization in individuals with visible skin conditions.
Methods: Items were generated by a verbatim report based on qualitative interviews with patients with various dermatologic conditions. Subsequently, a study was implemented for psychometric analysis. A dermatology-specific stigmatization questionnaire (PUSH-D) was refined via item reduction according to inter-question correlations, consensus among experts and exploratory factor analysis. Internal consistency was determined by calculating Cronbach's α. Concurrent validity was determined by calculating the correlation between PUSH-D and the Dermatology Life Quality Index (DLQI) and the Rosenberg Self-Esteem Scale (RSES).
Results: From a primary list of 22 items, PUSH-D was reduced to a 17-item questionnaire, covering two pertinent dimensions based on the exploratory factor analysis. Construct validity was demonstrated, and PUSH-D showed good internal consistency (Cronbach's α = 0.9). PUSH-D correlated strongly with the DLQI 0.72 (p < 0.001) and moderately with the RSES 0.49 (p < 0.001).
Conclusion: PUSH-D allows a comprehensive view of the degree of stigmatization in visible skin disorders, as well as the comparability of stigmatization levels across various skin conditions.
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Conflict of interest statement
Bertrand Chuberre and Delphine Kerob are employed by L'Oréal. Khaled Ezzedine; Jason Shourick; Christina Bergqvist; Laurent Misery; Bruno Halioua; Gaëlle Le Fur; Carle Paul; Marie‐Aleth Richard and Charles Taieb have no conflict of interest to declare.
Figures
Similar articles
-
Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) score.Br J Dermatol. 2024 Apr 17;190(5):712-717. doi: 10.1093/bjd/ljae020. Br J Dermatol. 2024. PMID: 38234050
-
Arabic language skin-related stigmatization instruments: Translation and validation process.Adv Clin Exp Med. 2019 Jun;28(6):825-832. doi: 10.17219/acem/102617. Adv Clin Exp Med. 2019. PMID: 30740941
-
Development and validation of an epidermolysis bullosa family/parental burden score.Br J Dermatol. 2015 Dec;173(6):1405-10. doi: 10.1111/bjd.14072. Epub 2015 Nov 4. Br J Dermatol. 2015. PMID: 26281012
-
Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review.Value Health. 2021 Aug;24(8):1158-1171. doi: 10.1016/j.jval.2021.02.006. Epub 2021 Apr 21. Value Health. 2021. PMID: 34372982
-
Stigmatization in Patients With Psoriasis: A Mini Review.Front Immunol. 2021 Nov 15;12:715839. doi: 10.3389/fimmu.2021.715839. eCollection 2021. Front Immunol. 2021. PMID: 34867945 Free PMC article. Review.
Cited by
-
Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial Melasma.Dermatol Ther (Heidelb). 2025 Sep;15(9):2379-2390. doi: 10.1007/s13555-025-01473-4. Epub 2025 Jun 30. Dermatol Ther (Heidelb). 2025. PMID: 40586974 Free PMC article.
-
Treat-to-Target in Atopic Dermatitis.Am J Clin Dermatol. 2024 Jan;25(1):91-98. doi: 10.1007/s40257-023-00827-y. Epub 2023 Dec 11. Am J Clin Dermatol. 2024. PMID: 38079107 Review.
-
Patient-Reported Outcomes among people living with Chronic Pruritus (PROs-CP): Protocol for a single-center, multistage, mixed-methods prospective cohort study in Thailand.PLoS One. 2025 Feb 10;20(2):e0314548. doi: 10.1371/journal.pone.0314548. eCollection 2025. PLoS One. 2025. PMID: 39928603 Free PMC article.
-
Alopecia Areata: Impact on Patients' Quality of Life and Disease Perception: A Survey-Based Study.Acta Derm Venereol. 2025 Jul 19;105:adv43318. doi: 10.2340/actadv.v105.43318. Acta Derm Venereol. 2025. PMID: 40682499 Free PMC article.
-
The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: A systematic review.J Eur Acad Dermatol Venereol. 2025 Mar;39(3):631-679. doi: 10.1111/jdv.20321. Epub 2024 Sep 13. J Eur Acad Dermatol Venereol. 2025. PMID: 39269008 Free PMC article.
References
-
- Tizek L, Schielein MC, Seifert F, Biedermann T, Böhner A, Zink A. Skin diseases are more common than we think: screening results of an unreferred population at the Munich Oktoberfest. J Eur Acad Dermatol Venereol. 2019;33:1421–8. - PubMed
-
- Fino E, Mazzetti M, Russo PM. Psoriasis‐related stigma and its intersection with intergroup bias in medical students. J Am Acad Dermatol. 2021;84:1432–4. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources